glp-1 and vision Popular Weight Loss Drugs Linked to Risk of Sudden Loss GLP-1s and Your Eyes: An

doi: 10.3390/cells11162587 94 WangGYanYXuNYinDHuiY

Notably, two participants exited the study due to anxiety (placebo group) and food aversion (liraglutide 1.2 mg group)

Additionally, with equivocal findings in DR and NAION, discussing personalized ocular risk of starting GLP-1RA in patients is key, and considering increased follow-up frequency after medication initiation may be warranted

For Wegovy-specific dose tracking, see the Wegovy Tracker and Wegovy Side Effect Tracker App pages

Pay attention to other signs, like shifts in your appetite or food cravings

Sequential therapy is more common in clinical practice, and decisions should be made promptly within 36 months and based on clinical or biochemical established goals